BE2016C056I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C056I2
BE2016C056I2 BE2016C056C BE2016C056C BE2016C056I2 BE 2016C056 I2 BE2016C056 I2 BE 2016C056I2 BE 2016C056 C BE2016C056 C BE 2016C056C BE 2016C056 C BE2016C056 C BE 2016C056C BE 2016C056 I2 BE2016C056 I2 BE 2016C056I2
Authority
BE
Belgium
Prior art keywords
antagonists
subject
present disclosure
disclosure
neutralize
Prior art date
Application number
BE2016C056C
Other languages
English (en)
French (fr)
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of BE2016C056I2 publication Critical patent/BE2016C056I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Luminescent Compositions (AREA)
  • Glass Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE2016C056C 2003-05-08 2016-10-24 BE2016C056I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46921103P 2003-05-08 2003-05-08
US55762104P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
EP04760993A EP1624892B1 (en) 2003-05-08 2004-05-10 Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
BE2016C056I2 true BE2016C056I2 (nl) 2023-08-09

Family

ID=33459144

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C056C BE2016C056I2 (nl) 2003-05-08 2016-10-24

Country Status (25)

Country Link
US (8) US20050025763A1 (nl)
EP (4) EP2371391B1 (nl)
JP (4) JP4887152B2 (nl)
KR (1) KR101268707B1 (nl)
CN (1) CN1805755B (nl)
AT (1) ATE506076T1 (nl)
AU (2) AU2004238363B2 (nl)
BE (1) BE2016C056I2 (nl)
BR (1) BRPI0410129B8 (nl)
CA (1) CA2523001C (nl)
CY (4) CY1111958T1 (nl)
DE (1) DE602004032328D1 (nl)
DK (3) DK2371391T3 (nl)
ES (2) ES2516840T3 (nl)
FR (1) FR16C1012I2 (nl)
HK (3) HK1089374A1 (nl)
HU (2) HUE034908T2 (nl)
LT (1) LT2853272T (nl)
LU (1) LU93274I2 (nl)
MX (1) MXPA05012011A (nl)
NL (1) NL300838I2 (nl)
PL (3) PL2853272T3 (nl)
PT (3) PT2371391E (nl)
SI (3) SI2853272T1 (nl)
WO (1) WO2004100898A2 (nl)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7842293B2 (en) * 2006-08-07 2010-11-30 Facet Biotech Corporation Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
SI2641601T1 (sl) 2006-08-07 2016-11-30 Abbvie Biotherapeutics Inc. Postopek za zdravljenje multiple mielome z uporabo kombinacijskih terapij, osnovanih na HuLuc63 z bortezomibom
WO2008019379A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
JP2011523560A (ja) * 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
EP2361263A1 (en) * 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
JP5818688B2 (ja) * 2009-01-08 2015-11-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド 核酸増幅反応の効率を改善するための方法および組成物
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
EA023700B1 (ru) 2010-01-28 2016-07-29 Глаксо Груп Лимитед Cd127-связывающие белки
ES2617283T3 (es) 2010-02-24 2017-06-16 Immunogen, Inc. Inmunoconjugados contra el receptor 1 de folato y usos de los mismos
CN108743965A (zh) 2011-04-01 2018-11-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
BR112015022119A2 (pt) * 2013-03-15 2017-08-29 Abbvie Biotherapeutics Inc Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
AU2014233478A1 (en) * 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
CN115028735A (zh) 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
US20160159918A1 (en) * 2013-07-24 2016-06-09 The General Hospital Corporation Methods for diagnosing and treating immune disease
UA120166C2 (uk) 2013-08-30 2019-10-25 Іммуноджен, Інк. Антитіло, що специфічно зв'язується з folr1, та спосіб виявлення рецептора фолієвої кислоти 1
WO2015057674A1 (en) 2013-10-14 2015-04-23 Club Car, Llc Self-preloading shift lever
WO2015069785A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
JP2017522289A (ja) * 2014-06-17 2017-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改善されたα−Ｖβ−８抗体
JP7113618B2 (ja) 2014-07-15 2022-08-05 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法用の操作された細胞
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EA201791049A1 (ru) 2014-12-04 2017-10-31 Бристол-Майерс Сквибб Компани Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
DE102015102183B4 (de) * 2015-02-16 2018-03-01 Robert Bosch Automotive Steering Gmbh Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug
KR102606190B1 (ko) 2015-02-20 2023-11-23 오하이오 스테이트 이노베이션 파운데이션 Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
WO2016168766A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
EP3313528B1 (en) 2015-06-29 2021-08-04 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
JP7222550B2 (ja) 2017-03-13 2023-02-15 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー ヒトエリスロフェロン抗体及びその使用
SG11201907923VA (en) * 2017-03-29 2019-09-27 Agency Science Tech & Res Anti oligosaccharide antibody
CN114058590A (zh) 2017-06-20 2022-02-18 居里研究所 Suv39h1缺陷的免疫细胞
AU2018315127B2 (en) * 2017-08-07 2021-12-23 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
MA50855A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Procédé de génération de compositions thérapeutiques de cellules modifiées
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
ES2971659T3 (es) 2017-11-01 2024-06-06 Juno Therapeutics Inc Procedimiento para la producción de una composición de células T
MA50860A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US20210207080A1 (en) 2017-12-08 2021-07-08 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
KR20200109308A (ko) 2017-12-08 2020-09-22 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법을 위한 표현형 마커 및 관련 방법
CN112004824A (zh) 2017-12-08 2020-11-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20210002358A1 (en) * 2018-03-05 2021-01-07 Linda Barone Anti-phf-tau antibodies and uses thereof
EP3814369A1 (en) 2018-06-29 2021-05-05 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
EP3833759A1 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
CN109406798A (zh) * 2018-10-29 2019-03-01 美康生物科技股份有限公司 肌酐酶法检测试剂盒
MX2021005024A (es) 2018-11-01 2021-07-21 Juno Therapeutics Inc Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
US20210393689A1 (en) 2018-11-01 2021-12-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods for activating inactive immune cells and cancer treatment
WO2020223571A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
BR112021021075A2 (pt) 2019-05-01 2021-12-14 Editas Medicine Inc Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
KR20220042161A (ko) 2019-07-23 2022-04-04 엥스띠뛰 퀴리 Suv39h1에 결함이 있는 면역 세포
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
KR20220137696A (ko) * 2020-02-05 2022-10-12 나보, 인크. 항-헵신 항체 및 그의 용도
US20230149462A1 (en) 2020-04-10 2023-05-18 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
EP4188395A1 (en) 2020-07-30 2023-06-07 Institut Curie Immune cells defective for socs1
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
US20240108654A1 (en) 2021-03-03 2024-04-04 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
EP4346912A1 (en) 2021-05-25 2024-04-10 Institut Curie Myeloid cells overexpressing bcl2
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024114691A1 (en) * 2022-12-02 2024-06-06 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO1996039518A1 (en) 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
CA2328895A1 (en) 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6020599A (en) 1998-08-25 2000-03-14 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
AU2757500A (en) 1999-02-10 2000-08-29 Human Genome Sciences, Inc. 33 human secreted proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US7232889B2 (en) * 1999-03-08 2007-06-19 Genentech, Inc. PRO300 antibodies
WO2000055627A1 (en) 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
CA2383254A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP3951035B2 (ja) 1999-09-01 2007-08-01 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CZ20023203A3 (cs) * 2000-03-24 2003-08-13 Micromet Ag Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D
WO2001091793A1 (en) 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
EA007388B1 (ru) * 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Модифицированные антитела и способы применения
EP1390390A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP2361263A1 (en) 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
CN104010774B (zh) 2011-09-15 2017-10-13 康富真信息技术股份有限公司 用于自动生成机器人程序的系统和方法
EP2814652B1 (en) 2012-02-13 2019-06-19 Radius Engineering Inc. Reusable cartridge for injection molding

Also Published As

Publication number Publication date
CA2523001A1 (en) 2004-11-25
KR20060018837A (ko) 2006-03-02
EP1624892B1 (en) 2011-04-20
PL2371391T3 (pl) 2015-01-30
BRPI0410129B1 (pt) 2020-02-11
SI2853272T1 (sl) 2017-10-30
DK2853272T3 (da) 2017-11-06
US20090238835A1 (en) 2009-09-24
ES2516840T3 (es) 2014-10-31
JP5976288B2 (ja) 2016-08-23
FR16C1012I2 (fr) 2019-01-11
NL300838I2 (nl) 2017-01-03
PL2853272T3 (pl) 2018-01-31
EP1624892A2 (en) 2006-02-15
HK1163497A1 (en) 2012-09-14
US9175081B2 (en) 2015-11-03
PT2371391E (pt) 2014-10-30
SI2371391T1 (sl) 2014-12-31
CY1115671T1 (el) 2017-01-25
AU2010214661B2 (en) 2012-05-17
BRPI0410129B8 (pt) 2021-05-25
US8445646B2 (en) 2013-05-21
WO2004100898A2 (en) 2004-11-25
US20140065063A1 (en) 2014-03-06
US20100168397A1 (en) 2010-07-01
EP3275463A1 (en) 2018-01-31
FR16C1012I1 (nl) 2016-09-12
JP6042834B2 (ja) 2016-12-14
JP2012121878A (ja) 2012-06-28
EP2371391A1 (en) 2011-10-05
US20090238827A1 (en) 2009-09-24
EP2853272B1 (en) 2017-08-02
BRPI0410129A (pt) 2006-05-16
LU93274I2 (fr) 2016-12-27
WO2004100898A3 (en) 2005-08-18
HK1089374A1 (en) 2006-12-01
US8008450B2 (en) 2011-08-30
US8133981B2 (en) 2012-03-13
US20050025763A1 (en) 2005-02-03
LT2853272T (lt) 2017-10-10
US10442859B2 (en) 2019-10-15
CN1805755A (zh) 2006-07-19
HUE034908T2 (hu) 2018-03-28
AU2004238363A1 (en) 2004-11-25
CY2016035I1 (el) 2017-09-13
US20160002335A1 (en) 2016-01-07
US20200031929A1 (en) 2020-01-30
JP2014139187A (ja) 2014-07-31
CA2523001C (en) 2013-12-31
CY1119353T1 (el) 2018-02-14
CY1111958T1 (el) 2015-11-04
US20120064083A1 (en) 2012-03-15
DE602004032328D1 (de) 2011-06-01
DK2371391T3 (da) 2014-11-03
PT2853272T (pt) 2017-08-30
AU2010214661A1 (en) 2010-09-16
CN1805755B (zh) 2011-06-01
MXPA05012011A (es) 2006-02-03
AU2004238363B2 (en) 2010-05-27
ES2643289T3 (es) 2017-11-22
ATE506076T1 (de) 2011-05-15
EP1624892A4 (en) 2007-08-08
KR101268707B1 (ko) 2013-05-29
HK1208815A1 (en) 2016-03-18
PT1624892E (pt) 2011-07-12
JP2007503465A (ja) 2007-02-22
JP4887152B2 (ja) 2012-02-29
SI1624892T1 (sl) 2011-08-31
PL1624892T3 (pl) 2011-09-30
EP2371391B1 (en) 2014-07-23
CY2016035I2 (el) 2017-09-13
EP2853272A1 (en) 2015-04-01
JP2017019795A (ja) 2017-01-26
DK1624892T3 (da) 2011-08-08
HUS1600042I1 (hu) 2016-11-28

Similar Documents

Publication Publication Date Title
NL300838I2 (nl)
DE602004029399D1 (nl)
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
MXPA06003788A (es) Anticuerpos completamente humanos contra 4-1bb humano (cd137).
DE60236646D1 (de) Anti-VEGF-2 Antikörper
EP2289550A3 (en) Ultra high affinity neutralizing antibodies
EP1411962A4 (en) MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2001090361A3 (en) Modulation of inflammation by protease-treated mcp-3 chemokine